267 related articles for article (PubMed ID: 29221876)
1. Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer: A Meta-analysis of Randomized Noninferiority Trials.
Royce TJ; Lee DH; Keum N; Permpalung N; Chiew CJ; Epstein S; Pluchino KM; D'Amico AV
Eur Urol Focus; 2019 Jul; 5(4):577-584. PubMed ID: 29221876
[TBL] [Abstract][Full Text] [Related]
2. Hypofractionation for clinically localized prostate cancer.
Hickey BE; James ML; Daly T; Soh FY; Jeffery M
Cochrane Database Syst Rev; 2019 Sep; 9(9):CD011462. PubMed ID: 31476800
[TBL] [Abstract][Full Text] [Related]
3. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
[TBL] [Abstract][Full Text] [Related]
4. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
Brand DH; Tree AC; Ostler P; van der Voet H; Loblaw A; Chu W; Ford D; Tolan S; Jain S; Martin A; Staffurth J; Camilleri P; Kancherla K; Frew J; Chan A; Dayes IS; Henderson D; Brown S; Cruickshank C; Burnett S; Duffton A; Griffin C; Hinder V; Morrison K; Naismith O; Hall E; van As N;
Lancet Oncol; 2019 Nov; 20(11):1531-1543. PubMed ID: 31540791
[TBL] [Abstract][Full Text] [Related]
5. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.
Fransson P; Nilsson P; Gunnlaugsson A; Beckman L; Tavelin B; Norman D; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Zackrisson B; Kjellén E; Franzén L; Widmark A
Lancet Oncol; 2021 Feb; 22(2):235-245. PubMed ID: 33444529
[TBL] [Abstract][Full Text] [Related]
6. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
[TBL] [Abstract][Full Text] [Related]
7. External beam radiation dose escalation for high grade glioma.
Khan L; Soliman H; Sahgal A; Perry J; Xu W; Tsao MN
Cochrane Database Syst Rev; 2020 May; 5(5):CD011475. PubMed ID: 32437039
[TBL] [Abstract][Full Text] [Related]
8. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
Aluwini S; Pos F; Schimmel E; Krol S; van der Toorn PP; de Jager H; Alemayehu WG; Heemsbergen W; Heijmen B; Incrocci L
Lancet Oncol; 2016 Apr; 17(4):464-474. PubMed ID: 26968359
[TBL] [Abstract][Full Text] [Related]
9. Moderate Hypofractionation in Intermediate- and High-Risk, Localized Prostate Cancer: Health-Related Quality of Life From the Randomized, Phase 3 HYPRO Trial.
Wortel RC; Oomen-de Hoop E; Heemsbergen WD; Pos FJ; Incrocci L
Int J Radiat Oncol Biol Phys; 2019 Mar; 103(4):823-833. PubMed ID: 30458234
[TBL] [Abstract][Full Text] [Related]
10. Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer.
Catton CN; Lukka H; Gu CS; Martin JM; Supiot S; Chung PWM; Bauman GS; Bahary JP; Ahmed S; Cheung P; Tai KH; Wu JS; Parliament MB; Tsakiridis T; Corbett TB; Tang C; Dayes IS; Warde P; Craig TK; Julian JA; Levine MN
J Clin Oncol; 2017 Jun; 35(17):1884-1890. PubMed ID: 28296582
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Treatment-Related Toxicity With Hypofractionated or Conventionally Fractionated Radiation Therapy for Prostate Cancer: A National Population-Based Study.
Sujenthiran A; Parry M; Nossiter J; Berry B; Cathcart PJ; Clarke NW; Payne H; van der Meulen J; Aggarwal A
Clin Oncol (R Coll Radiol); 2020 Aug; 32(8):501-508. PubMed ID: 32143901
[TBL] [Abstract][Full Text] [Related]
12. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
Wilkins A; Mossop H; Syndikus I; Khoo V; Bloomfield D; Parker C; Logue J; Scrase C; Patterson H; Birtle A; Staffurth J; Malik Z; Panades M; Eswar C; Graham J; Russell M; Kirkbride P; O'Sullivan JM; Gao A; Cruickshank C; Griffin C; Dearnaley D; Hall E
Lancet Oncol; 2015 Dec; 16(16):1605-16. PubMed ID: 26522334
[TBL] [Abstract][Full Text] [Related]
13. Hypofractionated radiotherapy versus conventional radiotherapy in patients with intermediate- to high-risk localized prostate cancer: a meta-analysis of randomized controlled trials.
Guo W; Sun YC; Bi JQ; He XY; Xiao L
BMC Cancer; 2019 Nov; 19(1):1063. PubMed ID: 31703647
[TBL] [Abstract][Full Text] [Related]
14. A systematic review of hypofractionation for primary management of prostate cancer.
Koontz BF; Bossi A; Cozzarini C; Wiegel T; D'Amico A
Eur Urol; 2015 Oct; 68(4):683-91. PubMed ID: 25171903
[TBL] [Abstract][Full Text] [Related]
15. Randomized Trial of Hypofractionated, Dose-Escalated, Intensity-Modulated Radiation Therapy (IMRT) Versus Conventionally Fractionated IMRT for Localized Prostate Cancer.
Hoffman KE; Voong KR; Levy LB; Allen PK; Choi S; Schlembach PJ; Lee AK; McGuire SE; Nguyen Q; Pugh TJ; Frank SJ; Kudchadker RJ; Du W; Kuban DA
J Clin Oncol; 2018 Oct; 36(29):2943-2949. PubMed ID: 30106637
[TBL] [Abstract][Full Text] [Related]
16. External beam radiation dose escalation for high grade glioma.
Khan L; Soliman H; Sahgal A; Perry J; Xu W; Tsao MN
Cochrane Database Syst Rev; 2016 Aug; (8):CD011475. PubMed ID: 27541334
[TBL] [Abstract][Full Text] [Related]
17. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.
Incrocci L; Wortel RC; Alemayehu WG; Aluwini S; Schimmel E; Krol S; van der Toorn PP; Jager H; Heemsbergen W; Heijmen B; Pos F
Lancet Oncol; 2016 Aug; 17(8):1061-1069. PubMed ID: 27339116
[TBL] [Abstract][Full Text] [Related]
18. Hypofractionated versus conventionally fractionated image-guided volumetric-modulated arc radiotherapy for localized prostate cancer: a phase II randomized trial from China.
Zhong QZ; Xia X; Gao H; Xu YG; Zhao T; Wu QH; Wang D; Lin HL; Sha XY; Liu M; Li GF
Aging (Albany NY); 2021 Feb; 13(5):6936-6944. PubMed ID: 33653964
[TBL] [Abstract][Full Text] [Related]
19. Toxicity after moderately hypofractionated versus conventionally fractionated prostate radiotherapy: A systematic review and meta-analysis of the current literature.
Francolini G; Detti B; Becherini C; Caini S; Ingrosso G; Di Cataldo V; Stocchi G; Salvestrini V; Lancia A; Scartoni D; Giacomelli I; Sardaro A; Carbonara R; Borghesi S; Aristei C; Livi L
Crit Rev Oncol Hematol; 2021 Sep; 165():103432. PubMed ID: 34352361
[TBL] [Abstract][Full Text] [Related]
20. Ultrahypofractionated versus hypofractionated and conventionally fractionated radiation therapy for localized prostate cancer: A systematic review and meta-analysis of phase III randomized trials.
Lehrer EJ; Kishan AU; Yu JB; Trifiletti DM; Showalter TN; Ellis R; Zaorsky NG
Radiother Oncol; 2020 Jul; 148():235-242. PubMed ID: 32505965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]